Dr. Thomas Joos joined 1998 the NMI at the University of Tuebingen heading the department of biochemistry. Since 2013 he is the deputy managing director of NMI. His research is focused on miniaturized multiplexed immunoassays for biomarker research and diagnostic applications. Dr. Joos studied Biochemistry at the University of Tubingen. He performed his Ph.D. degree in 1985 on integrin‐alpha5 during early embroygenesis of Xenopus laevis in the laboratory of Prof. Peter Hausen at the Max‐Planck‐Institute of Developmental Biology.
Dr. Joos is a member of the editorial board of Drug Discovery Today, Proteomics, Molecular Biotechnology and Expert Review of Proteomics. He is a member of the scientific advisory board of the "Plasma Proteome Institute" Washington, DC, USA, of the “AlbaNova VINN Excellence Centre for Protein Technology (ProNova)” at the Royal Institute of Technology, Stockholm, Sweden, and of Myriad‐RBM, Austin, TX, USA.